Format
Sort by

Send to

Choose Destination

Search results

Items: 12

1.

TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients.

Liang S, Aiqun M, Jiwu L, Ping Z.

Immunol Res. 2016 Apr;64(2):424-30. doi: 10.1007/s12026-015-8685-6.

PMID:
26318748
2.

Healing arterial ulcers: Endothelial lining regeneration upon vascular denudation injury.

McDonald AI, Iruela-Arispe ML.

Vascul Pharmacol. 2015 Sep;72:9-15. doi: 10.1016/j.vph.2015.06.007. Epub 2015 Jun 18. Review.

3.

Novel potential targets for prevention of arterial restenosis: insights from the pre-clinical research.

Forte A, Rinaldi B, Berrino L, Rossi F, Galderisi U, Cipollaro M.

Clin Sci (Lond). 2014 Dec;127(11):615-34. doi: 10.1042/CS20140131. Review.

PMID:
25072327
4.

Inhibition of Orai1-mediated Ca(2+) entry is a key mechanism of the antiproliferative action of sirolimus in human arterial smooth muscle.

König S, Browne S, Doleschal B, Schernthaner M, Poteser M, Mächler H, Wittchow E, Braune M, Muik M, Romanin C, Groschner K.

Am J Physiol Heart Circ Physiol. 2013 Dec 1;305(11):H1646-57. doi: 10.1152/ajpheart.00365.2013. Epub 2013 Sep 20.

5.

Recent advances in coronary angioscopy.

Uchida Y.

J Cardiol. 2011 Jan;57(1):18-30. doi: 10.1016/j.jjcc.2010.11.001. Epub 2010 Dec 10. Review.

6.

Cellular and molecular changes associated with inhibitory effect of pioglitazone on neointimal growth in patients with type 2 diabetes after zotarolimus-eluting stent implantation.

Hong SJ, Kim ST, Kim TJ, Kim EO, Ahn CM, Park JH, Kim JS, Lee KM, Lim DS.

Arterioscler Thromb Vasc Biol. 2010 Dec;30(12):2655-65. doi: 10.1161/ATVBAHA.110.212670. Epub 2010 Oct 28.

7.

Molecular basis of different outcomes for drug-eluting stents that release sirolimus or tacrolimus.

Giordano A.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):159-68. Review.

PMID:
20205050
8.

Molecular basis of restenosis and novel issues of drug-eluting stents.

Inoue T, Node K.

Circ J. 2009 Apr;73(4):615-21. Epub 2009 Mar 13. Review.

9.

Molecular basis of restenosis and drug-eluting stents.

Costa MA, Simon DI.

Circulation. 2005 May 3;111(17):2257-73. Review. No abstract available.

10.

Rationale and study design of the CardioGene Study: genomics of in-stent restenosis.

Ganesh SK, Skelding KA, Mehta L, O'Neill K, Joo J, Zheng G, Goldstein J, Simari R, Billings E, Geller NL, Holmes D, O'Neill WW, Nabel EG.

Pharmacogenomics. 2004 Oct;5(7):952-1004.

PMID:
15469413
11.

Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug?

Radke PW, Weber C, Kaiser A, Schober A, Hoffmann R.

Curr Pharm Des. 2004;10(4):349-55. Review.

PMID:
14965196
12.

Rapamycin: signaling in vascular smooth muscle.

Marks AR.

Transplant Proc. 2003 May;35(3 Suppl):231S-233S.

PMID:
12742501
Items per page

Supplemental Content

Loading ...
Write to the Help Desk